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Background: The aetiology of male breast cancer (MBC) is poorly understood. In 
particular, the extent to which the genetic basis of MBC differs from female breast 
cancer (FBC) is unknown. A previous genome-wide association study (GWAS) of 
MBC identified two predisposition loci for the disease, both of which were also 
associated with risk of FBC. 
Methods: We performed genome-wide single nucleotide polymorphism (SNP) 
genotyping of European ancestry MBC case subjects and controls, in three stages. 
Associations between directly genotyped and imputed SNPs with MBC were 
assessed using fixed-effects meta-analysis of 1,380 cases and 3,620 controls. 
Replication genotyping of 810 cases and 1,026 controls was used to validate 
variants with P-values < 1 x 10-06. Genetic correlation with FBC was evaluated using 
LD score regression, by comprehensively examining the associations of published 
FBC risk loci with risk of MBC and by assessing associations between a FBC 
polygenic risk score (PRS) and MBC. All statistical tests were two-sided. 
Results: The GWAS identified three novel MBC susceptibility loci that attained 
genome-wide significance (P < 5 x 10-08). Genetic correlation analysis revealed a 
strong shared genetic basis with estrogen-receptor (ER) positive FBC. Males in the 
top quintile of genetic risk had a four-fold increased risk of breast cancer relative to 
those in the bottom quintile (odds ratio = 3.86, 95% confidence interval = 3.07 to 
4.87, P = 2.08 x 10-30). 
Conclusions: These findings advance our understanding of the genetic basis of 
MBC, providing support for an overlapping genetic aetiology with FBC and identifying 
a four-fold high risk group of susceptible men.  
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Male breast cancer (MBC) is rare, accounting for fewer than 1% of all breast 
cancer diagnoses. A greater proportion of male than female breast cancers (FBC) 
are of the estrogen-receptor (ER) positive subtype (>95% MBC vs. 75% FBC) 
suggesting that MBC may comprise a more homogeneous group of tumours than 
FBC. Although there is a paucity of data regarding the aetiology of MBC, family 
history and genetic susceptibility are important risk factors (1, 2). Approximately 10% 
of cases are attributable to inherited mutations in BRCA2 (1). Conversely, mutations 
in BRCA1 are observed in only a small number of cases suggesting differences in 
the underlying genetic aetiologies of MBC and FBC (1). 
Common germline variants influence susceptibility to MBC (3-5). Our previous 
genome-wide association study (GWAS) of MBC identified single nucleotide 
polymorphisms (SNPs) at 14q24.1 and 16q12.1 that were associated with 
susceptibility at genome-wide levels of significance (4). Moreover, although these 
loci were also associated with FBC susceptibility (6, 7), they conferred greater risks 
of breast cancer in men than women (14q24.1 odds ratio [OR] = 1.57 vs 1.07 and 
16q12.1 OR = 1.50 vs 1.22 for MBC and FBC respectively) (4), lending weight to 
findings from population-based family-history studies which suggest a greater 
contribution of genetic variation to MBC than FBC predisposition (2).  
In this study we have pooled individual-level data from our GWAS (4) with two 
additional case-control datasets to identify novel MBC risk variants, to illuminate 
better the genetic basis of MBC and to enable comparisons between determinants of 







Cases for discovery analysis were primarily from the Breast Cancer Now Male 
Breast Cancer Study, a population-based case-control study of MBC in England and 
Wales (UK-BCN-MBCS, n = 1,210). Additional cases were from UK studies at the 
University of Leeds (UK-UoL, n = 31) and the University of Cambridge (UK-UoC, n = 
138), and a US study at City of Hope (US-CoH, n = 113). The UK-UoL, UK-UoC, US-
CoH and 540 of the UK-BCN-MBCS cases have been analysed previously (4). Here 
we have added an additional 670 MBC cases from the UK-BCN-MBCS. To estimate 
autosomal SNP genotype frequencies from the general population, we used male 
and female controls from the 1958 British Birth Cohort (UK-58BC, n = 2,663), male 
controls from the UK-BCN-MBCS (n = 264) and female controls from the UK 
Generations Study (UK-GS, n = 698) (Supplementary Table 1) (8). The inclusion of 
female controls was predicated upon the observation that autosomal SNPs do not 
differ in frequency between males and females sampled from the same ancestral 
population so that GWAS of sexually differentiated traits, such as breast cancer, 
need not be restricted to selection of same sex controls (9). Descriptions of each of 
the studies that were used for discovery analysis are provided in Supplementary 
Methods. For validation of promising associations, we used 810 cases and 1,026 
controls of European ancestry that were assembled internationally for our previous 
GWAS (Supplementary Table 1) (4). All sample collection was undertaken with 





Genotyping, Quality Control and Imputation 
Discovery analysis samples, genotyping arrays and SNPs / samples excluded 
during quality control are summarised in Supplementary Figure 1. Genotyping was 
performed using Illumina (San Diego, CA) Infinium OmniExpress 710K BeadChips 
(OE; UK-BCN-MBCS, UK-UoL, UK-UoC and US-CoH cases), Infinium OncoArray 
500K BeadChips (OA; UK-BCN-MBCS cases and UK-GS controls) and Infinium 
Global Screening Array 640K BeadChips (GSA; UK-BCN-MBCS cases and 
controls). UK-58BC controls were genotyped using Infinium 1.2M BeadChips. 
Replication genotyping was performed using either Agena (San Diego, CA) iPLEX 
chemistry or with KASP assays (LGC, Hoddesdon, UK). 
Samples were excluded based upon genotyping completion rate (< 95.0%), 
relatedness (IBD first- and second-degree relatives) and genetically determined non-
European ancestry. SNPs were excluded according to call rates (< 95.0%), MAF (< 
2.0%) and genotype deviation from Hardy-Weinberg proportions (P < 1 x 10-05). SNP 
data from cases genotyped using OE BeadChips was harmonised with UK-58BC 
control data yielding 486,160 SNPs. Cases and controls genotyped using OA were 
similarly harmonised, as were those using GSA. Genome-wide imputation was 
performed for each GWAS dataset using 1KGP Phase 3 reference data. Haplotypes 
were pre-phased using SHAPEIT2 (10) and imputation was performed using 
IMPUTE2 (11). Imputed SNPs with INFO scores < 0.80 and / or MAFs < 2.0% were 
excluded. After QC, 8,074,073 SNPs were available for analysis. 
 
Statistical Analysis 
For each GWAS dataset, tests of association between imputed SNPs and 
MBC status were performed, assuming a log-additive model, using SNPTEST v2.5 
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(12). Quantile–quantile plots showed no evidence of over-dispersion (λ = 0.99 to 
1.05, Supplementary Figure 2). Combined analysis of each dataset was performed 
using fixed-effects inverse variance-weighted meta-analysis (Supplementary Figure 
3) (13). Heterogeneity was assessed using Cochran’s Q-test and I2 statistics. 
Sensitivity analyses of the effect estimates when US-CoH cases or UK-GS and UK-
58BC female controls were omitted were consistent with the main results 
(Supplementary Tables 2 and 3). For replication analysis, effects under a log-
additive model were estimated by performing multiple logistic regression, adjusted 
for study, using the Genotype Libraries and Utilities package (14). Bayesian false 
discovery probabilities (BDFP) were calculated to assess the noteworthiness of FBC 
predisposition SNP associations with MBC assuming that the cost of a false non-
discovery was four times that of a false discovery (giving a noteworthiness cut-off 
value of 0.80) and that the OR lies between 0.83 and 1.2 with probability 0.95 (15). 
These comparisons were restricted to 172 published loci with FBC P < 5 x 10-08 (16). 
To compare the MBC ORs with those of FBC, we assumed both sets of ORs were 
log-normally distributed and that the difference between the log ORs was normally 
distributed with mean zero and variance equal to the sum of the squared standard 
errors of the two estimates to obtain a c2 statistic. All statistical tests were two-sided 
and P < .05 was used as the cut point for statistical significance unless otherwise 
stated. 
 
Heritability and Genetic Correlation 
The heritability of MBC, ℎ!", was estimated assuming a continuous underlying 
liability and an MBC population prevalence of 0.1%, using LD score regression 
(LDSC) (17). LDSC was used to calculate the genetic correlation, "!, between MBC 
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and FBC using summary statistics from 122,977 FBC cases and 105,974 controls in 
the Breast Cancer Association Consortium (BCAC) (16). Subtype specific genetic 
correlations between MBC and both ER-positive and ER-negative FBC also used 
BCAC data (n = 69,501 ER-positive and n = 21,468 ER-negative cases). To assess 
cross-cancer genetic correlations with other hormonally driven cancers we used 
summary statistics from 79,148 prostate cancer cases and 61,106 controls in the 
PRACTICAL consortium (18) and 22,406 invasive epithelial ovarian cancer cases 
and 40,941 controls in the OCAC consortium (19).  
 
Polygenic Risk Score Analysis 
A 313-SNP FBC polygenic risk score (PRS) (20) was calculated using effect 
estimates for overall, ER-positive and ER-negative FBC, standardised such that the 
PRS distribution in controls (2,663 male and female individuals from the UK-58BC) 
had mean = 0 and standard deviation = 1. The 313-SNP FBC PRS includes 305 
SNPs that were associated with overall FBC at P < 1 x 10-05 plus six additional SNPs 
that were associated with ER-positive FBC and two rare variants in the BRCA2 and 
CHEK2 genes (20). To enable comparison with FBC, we derived PRS for 1,671 
female cases from UK-GS (9). Logistic regression was used to estimate risk of MBC 
by quintiles and per standard deviation increase in the PRS.  
 
Gene Expression and eQTL Analysis 
Expression quantitative trait locus (eQTL) analyses were performed using 
GTEx gene expression data on normal breast samples from 157 males and 107 
females (21). Associations between log10 normalised gene-counts of candidate 
target-genes and SNP genotypes were assessed using linear regression, with and 
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without interaction terms for genotype and sex. Linear regression was used to 
assess associations between gene-expression of putative target-genes and sex. 
 
Results 
Heritability of MBC and Genetic Correlation With FBC 
After quality control, the three GWAS datasets yielded SNP genotypes at 
8,074,073 loci in 1,380 MBC cases and 3,620 controls. The heritability of MBC 
attributable to common SNPs, ℎ!", was 0.09 (SE = 0.06) on the liability scale, which is 
accordant with published estimates for FBC (22). Using cross-trait LDSC, we 
observed strong genetic correlation, "!, between MBC and FBC ("!= 0.83, SE = 0.30, 
P =.005). Consistent with the predominance of ER-positive tumours in MBC, genetic 
correlation was stronger between MBC and ER-positive FBC ("!= 0.82, SE = 0.30, P 
= .005), than ER-negative FBC ("!= 0.47, SE = 0.24, P = .047). Predicated on 
evidence of pleiotropy between breast cancer and other hormonally driven epithelial 
tumours (23), we estimated genetic correlation between MBC and both prostate and 
ovarian cancer. While there was no evidence of genetic correlation with prostate 
cancer ("!= 0.01, SE = 0.11, P = .90) there was borderline evidence of a moderate 
genetic correlation with ovarian cancer ("!= 0.55, SE = 0.29, P = .06). 
 
GWAS and Validation Analysis 
Combined analysis of the GWAS datasets detected a novel genome-wide 
statistically significant association (P < 5 x 10-08) between SNP rs9371545 at 6q25.1 
and risk of MBC (P = 1.63 x 10-08, Table 1, Supplementary Table 4) and validated 
the associations at 14q24.1 (rs1022979 P = 1.53 x 10-16) and 16q12.1 (rs35850695 
P = 1.57 x 10-11, Supplementary Table 4). We observed promising associations (P 
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< 1 x 10-06) at 11q13.3 (rs78540526 and rs554219, Table 1, Supplementary Table 
4) and 15q24 (rs4407020, Supplementary Table 4). Replication genotyping of 810 
cases and 1,026 controls provided support for rs78540526 and rs554219 (Table 1, 
Supplementary Table 4, Supplementary Figure 4), but not rs4407020 
(Supplementary Table 4) in a joint analysis with the discovery data (rs78540526 P 
= 1.06 x 10-11, rs554219 P = 2.86 x 10-11). Similar to the loci at 14q24.1 and 16q12.1, 
the 6q25.1 and 11q13.1 SNPs are also associated with predisposition to FBC but 
have larger risk effects in males (Table 1). 
 
Associations Between FBC Predisposition SNPs and Risk of MBC 
We next evaluated the MBC associations of 172 published FBC risk SNPs 
(16) (Supplementary Table 5). Thirty-five SNPs (20.3%) had P < .05 and consistent 
directions of effect with FBC; 33 remained noteworthy using BFDP analysis (15). 
Eight loci had statistically significant differences in their ORs for MBC and FBC (FDR 
< 0.10, Table 2, Supplementary Table 6). At 6q25.1 and 14q24.1, rs9397437 and 
rs2588809 had ORs that were greater for MBC than FBC, while rs2981578 at 
10q26.13 had an OR that was greater for FBC. The directions of the ORs for 
rs4233486 at 1p34.2, rs12710696 at 2p24.1, rs13066793 at 3p12.1, rs3215401 at 
5p15.33 and rs10816625 at 9q31.2 were opposite to FBC. 
At each of the 172 loci we investigated whether any variants correlated (r2 ≥ 
0.10) with a published FBC susceptibility SNP were more statistically significantly 
associated with MBC in our GWAS than the FBC SNP itself (Supplementary Table 
5). We identified four such SNPs with P < 1 x 10-05, at 6q25.1, 10p12.31 and 
11q13.3, which we genotyped alongside the corresponding lead FBC predisposition 
SNPs in our replication samples and analysed jointly with the discovery data (Figure 
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1, Table 3, Supplementary Table 5). At 6q25.1, rs9383938 (P = 2.93 x 10-09) was 
correlated with FBC SNP rs9397437 (P = 5.29 x 10-09, r2 = 0.83) but was nominally 
more statistically significantly associated with MBC. SNP rs146723925 was 
correlated (r2 = 0.89) with a second FBC risk locus at 6q25.1 demarcated by 
rs3757322 and was more statistically significantly associated with MBC in the 
discovery data, but failed assay design for replication genotyping. However, 
rs3757322 surpassed the genome-wide significance threshold following joint 
analysis (P = 6.23 x 10-09) and conditional analyses indicated that rs3757322 and 
rs9383938 tag independent causal alleles at 6q25.1 (Supplementary Table 7). At 
10p12.31, rs2183271 (P = 2.69 x 10-07) was several orders of magnitude more 
strongly associated with MBC than lead FBC SNP rs7072776 (P = 2.46 x 10-04, r2 = 
0.68) and the effect of rs7072776 was strongly dependent upon rs2183271 (Figure 
1, Table 3, Supplementary Tables 5 and 7). At 11q13.3, rs78540526 (P = 1.06 x 
10-11) was correlated with FBC SNP rs75915166 (P = 7.71 x 10-08, r2 = 0.63, Figure 
1, Table 3, Supplementary Table 5). rs75915166 and a second variant at 11q13.3, 
rs554219, have been reported to independently influence risk of FBC (24). Analysis 
of these SNPs conditioned on rs78540526 did not provide compelling evidence for 
independence in MBC (P-values = .64 and .03 respectively). However, rs554219 (P 
= 4.74 x 10-05; Supplementary Table 7), and rs78540526 (P = 5.55 x 10-05) were 
associated with MBC after conditioning on rs75915166. 
 
FBC PRS Association With MBC 
Since our data supported a strong genetic correlation between MBC and FBC, 
we assessed whether a recent 313-SNP FBC PRS (20) was associated with breast 
cancer risk in our study. The OR per standard deviation increase in the PRS was 
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1.55, 95% confidence interval (CI) = 1.45 to 1.66, P = 3.54 x 10-37 (Table 4). Men in 
the top quintile of genetic risk had an almost four-fold increased risk of breast cancer 
(OR = 3.86, 95% CI = 3.07 to 4.87, P = 2.08 x 10-30) compared with men in the 
bottom quintile. We examined MBC associations with the 313-SNP PRS 
incorporating weightings for ER-positive or ER-negative FBC. Risk estimates for the 
ER-positive PRS were similar to the overall PRS; the ER-negative PRS was less 
strongly associated with MBC risk (Table 4), consistent with our genetic correlation 
analysis. The PRS distribution in male cases was similar to that of FBC cases 
(Figure 2). 
 
Candidate Target-gene Expression in Male and Female Breast Tissue 
Functional studies have identified putative target-genes for five of the eight 
FBC predisposition loci that had statistically significant differences in their ORs for 
FBC and MBC: TERT at 5p15.33, ESR1 and CCDC170 at 6q25.1, KLF4 at 9q31.2, 
FGFR2 at 10q26.13 and ZFP36L1 at 14q24.1 (25-30). By examining GTEx multi-
tissue expression quantitative trait locus (eQTL) analyses (31) we suggest that 
CITED4 (rs4233486 P = 2.36 x 10-11) and VGLL3 (rs13066793 P = 1.21 x 10-07) are 
candidate target-genes at the loci mapping to 1p34.2 and 3p12.1 (21). CITED4 
encodes Cbp/p300-interacting transactivator 4, a transcriptional coactivator that is 
induced during lactogenic differentiation of breast epithelial cells and is involved in 
milk secretion (32) while VGLL3 encodes transcription cofactor vestigial-like protein 
3 and may act as a tumour suppressor gene in high-grade serous ovarian carcinoma 
(33). 
We hypothesised that variation in the basal gene expression levels of 
predisposition SNP target-genes in male and female breast tissue might partly 
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explain the different MBC and FBC risks observed at these loci. To investigate, we 
evaluated GTEx RNA-seq data from 157 males and 107 females. Four candidate 
target-genes had statistically significant sex-biased tissue expression 
(Supplementary Figure 5). CITED4 at 1p34.2 (P = 3.00 x 10-25) and FGFR2 at 
10q26.13 (P = 3.24 x 10-10) had higher expression in female than male breast tissue, 
while KLF4 at 9q31.2 (P = 9.10 x 10-10) and CCD170 at 6q25.1 (P = 2.80 x 10-04) 
were more highly expressed in males than females.  
 
We also assessed eQTL associations between the lead SNPs at these loci 
and their candidate target-genes using GTEx data from breast tissue (n = 264). The 
risk allele of rs13066793 at 3p12.1 was associated with reduced expression of 
VGLL3 (P = .02, Supplementary Figure 6), albeit the association was not 
statistically significant after adjusting for multiple comparisons. SNP rs3757322 at 
6q25.1 was borderline associated with expression of CCDC170 (P = .06) and this 
association varied according to sex (P = .02, Supplementary Figure 7). There was 
no evidence of breast-specific eQTL associations with target-genes at the other loci, 
which could reflect limited power to detect subtle differences in gene expression. 
 
Discussion 
We have performed the largest genetic association study of MBC to date by 
conducting, as is usual in GWAS, genome-wide imputation and meta-analysis of 
existing (4) and newly generated genotyping data. We identified three novel MBC 
predisposition loci that attained genome-wide levels of significance, of which two 
mapped to 6q25.1 and one mapped to 11q13.3, bringing the total number of 
confirmed predisposition loci to five. Notably, each of these loci is also associated 
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with risk of FBC and almost 20% of confirmed FBC susceptibility SNPs showed 
evidence of association with MBC predisposition. To date, no low penetrance alleles 
have been identified that are exclusively associated with MBC but not FBC. Although 
our study does not rule out the possibility that such loci exist, it does suggest that the 
magnitudes of their effects will be small. While differences between the frequencies 
of pathogenic BRCA1 and BRCA2 mutations have led to the suggestion that MBC 
and FBC have distinct genetic aetiologies, our genetic correlation analysis provides 
evidence of a shared genetic basis for MBC and ER-positive FBC. Interestingly, we 
detected borderline evidence (P = .06) of a cross-cancer genetic correlation between 
MBC and ovarian cancer, consistent with a recently reported genetic correlation 
between FBC and ovarian cancer (22). 
Lecarpentier et al recently demonstrated that a FBC PRS is associated with 
breast cancer risk in male BRCA1/2 mutation carriers (34). We show here, for the 
first time, that a FBC PRS is associated with MBC risk in men from the general 
population. The OR per standard deviation increase in the PRS for males is almost 
identical to that of unselected females and is greater than that of male BRCA1/2 
mutation carriers (20, 34, 35). While risk stratification amongst the general 
population using a PRS is unfeasible given both the rarity of MBC and level of risk 
differentiation, the striking similarity between the PRS distributions of MBC and FBC 
cases suggests that a larger number of FBC predisposition variants than were 
detected by our study probably influence susceptibility to MBC.  
Although our genetic correlation analysis indicated that MBC shares a 
pronounced genetic basis with ER-positive FBC, there are distinctions. For example, 
we observed several MBC associations amongst SNPs that confer greater risks of 
ER-negative than ER-positive FBC, including SNP rs9371545 at 6q25.1 and the 
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BRCA2 truncating variant rs11571833. Conversely, several SNPs that are most 
strongly associated with ER-positive FBC were not associated with MBC including 
rs11249433 at 1p11.2, rs34005590 at 2q35 and rs2981578 at 10q26.13. Whilst this 
may be a consequence of power, the ER-positive FBC OR for rs2981578 is large 
and should be detectable in our study. We hypothesise that the underlying 
aetiological mechanisms affected by SNPs that had statistically significant 
differences in their ORs for MBC and FBC might be influenced by sex-specific 
differences in expression or activity of their target-genes, or by different endogenous 
factors in males and females. The comparatively lower expression of FGFR2 in male 
than female breast tissue, as observed in GTEx data, could explain the lack of an 
MBC association with rs2981578 at the 10q26.13 locus, despite it being amongst the 
most strongly associated SNPs with ER-positive FBC.  
The principal limitation of our study was its relatively small size compared to 
typical cancer GWAS. Consequently, it had limited capacity to detect MBC 
predisposition loci that are associated with small risk effects and much larger studies 
will be needed for their discovery. The merits, or otherwise, of continually striving to 
identify polygenic determinants of disease susceptibility that confer relatively small 
effects have been debated extensively, particularly since they may have limited 
clinical usefulness in the short-term. However, all statistically robust genetic 
associations (even those with small effects) are underpinned by risk alleles that 
perturb biological processes, of which some might harbour effective targets for 
therapeutic intervention (36), thus justifying efforts that could lead to their detection. 
The subsequent illumination of the target-genes and pathways that underlie risk 
associations in MBC will also likely be difficult, not least because of a paucity of cell-
line models derived from male breast tumours for functional analysis. In conclusion, 
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our findings indicate several elements of shared genetic basis for susceptibility to 
MBC and FBC, provide further support for a polygenic component to MBC 
susceptibility and advance our understanding of the genetics of MBC development. 
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Table 1. Three novel risk variants with P < 5 x 10-08 identified from analysis of GWAS and replication data and their ORs for 
FBC. 
Cytoband SNP Allelesb Stage Control MAF 
Case 
MAF MBC OR (95% CI) P-value
c FBC OR (95% CI)d P-hete I2 
6q25.1 rs9371545a G/A  GWAS 0.07 0.10 1.60 (1.36-1.89) 1.63 x 10-08 - - - 
 rs9383938a G/T Replication 0.09 0.11 1.30 (1.04-1.63) .02 - - - 
   Joint - - 1.47 (1.30-1.67) 2.93 x 10-09 1.11 (1.08-1.14) 9.56 x 10-06 94.9 
11q13.3 rs554219 C/G GWAS 0.12 0.16 1.42 (1.24-1.62) 1.86 x 10-07 - - - 
   Replication 0.11 0.16 1.52 (1.25-1.84) 2.65 x 10-05 - - - 
   Joint - - 1.45 (1.31-1.62) 2.86 x 10-11 1.27 (1.24-1.31) .02 82.9 
11q13.3 rs78540526 C/T GWAS 0.07 0.10 1.58 (1.34-1.87) 7.38 x 10-08 - - - 
   Replication 0.06 0.10 1.68 (1.32-2.14) 2.45 x 10-05 - - - 
   Joint - - 1.61 (1.40-1.85) 1.06 x 10-11 1.39 (1.35-1.42) .04 76.2 
a SNP rs9383938 is a proxy for rs9371545 (r2 = 0.90) which failed assay design for replication genotyping. Summary statistics for replication and joint analysis 
are based on rs9383938. 
b Alleles are shown as major/minor allele based on control frequencies. 
c MBC P-values were derived from fixed-effects inverse variance-weighted meta-analysis (GWAS and Joint) and from multiple logistic regression, adjusted for 
study (Replication). All tests were two-sided. 
d ORs for ER-positive FBC from (16). 
e P-value for Cochran’s Q-test for heterogeneity between the MBC and FBC ORs. 
- Control and case MAFs were not calculated for meta-analysed SNPs at the joint analysis stage. FBC OR, P-het and I2 are not applicable for GWAS and 
replication stages since published FBC ORs were compared only to the MBC ORs estimated in joint analysis of our GWAS and replication studies. 
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Table 2. FBC predisposition SNPs with FDR adjusted P < .10 that confer statistically significantly different risk effects in 
males and females. 
Cytoband SNP Allelesa MBC OR (95% CI) FBC OR (95% CI)b P-valuec PFDR 
1p34.2 rs4233486 T/C 1.12 (1.02-1.23) 0.97 (0.95-0.98) .003 .09 
2p24.1 rs12710696 C/T 0.87 (0.79-0.95) 1.03 (1.01-1.04) 7.75 x 10-04 .03 
3p12.1 rs13066793 A/G 1.28 (1.08-1.51) 0.94 (0.91-0.97) 4.68 x 10-04 .03 
5p15.33 rs3215401 A/AG 1.10 (1.00-1.21) 0.93 (0.91-0.95) 7.63 x 10-04 .03 
6q25 rs9397437 G/A 1.58 (1.34-1.87) 1.17 (1.14-1.21) 4.15 x 10-04 .03 
9q31.2 rs10816625 A/G 0.85 (0.71-1.03) 1.11 (1.07-1.15) .004 .09 
10q26.13 rs2981578 T/C 1.08 (0.99-1.18) 1.23 (1.21-1.25) .004 .09 
14q24.1 rs2588809 C/T 1.59 (1.41-1.78) 1.06 (1.03-1.08) 1.25 x 10-10 2.15 x 10-08 
a Alleles are shown as major/minor allele based on control frequencies. 
b ORs for FBC from (16). 
c P-value for statistical significance of the difference between MBC and FBC log ORs.
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Table 3. Four FBC predisposition loci at which variants correlated at r2 ≥ 0.10 with a published FBC susceptibility SNP 
were more statistically significantly associated with MBC than the lead FBC SNP.  
Cytoband SNPa Allelesb Stage Control MAF Case MAF OR (95% CI) P-valuec 
6q25.1 rs3757322 T/G GWAS 0.33 0.37 1.23 (1.12-1.35) 1.11 x 10-05 
   Replication 0.33 0.39 1.32 (1.15-1.52) 9.53 x 10-05 
   Joint - - 1.26 (1.16-1.36) 6.23 x 10-09 
 rs146723925 GAA/G GWAS 0.35 0.39 1.23 (1.13-1.35) 7.73 x 10-06 
 r2 = 0.89  Replication - - Failed assay design - 
   Joint - - - - 
6q25.1 rs9397437 G/A GWAS 0.07 0.10 1.58 (1.34-1.87) 4.22 x 10-08 
   Replication 0.07 0.10 1.33 (1.05-1.69) .02 
   Joint - - 1.50 (1.31-1.71) 5.29 x 10-09 
 rs9383938 G/T GWAS 0.08 0.11 1.60 (1.36-1.89) 1.63 x 10-08 
 r2 = 0.83  Replication 0.09 0.11 1.30 (1.04-1.63) .02 
   Joint - - 1.47 (1.30-1.67) 2.93 x 10-09 
10p12.31 rs7072776 G/A GWAS 0.27 0.30 1.17 (1.06-1.29) .002 
   Replication 0.28 0.31 1.15 (0.99-1.33) .06 
   Joint - - 1.16 (1.07-1.26) 2.46 x 10-04 
 rs2183271 T/C GWAS 0.36 0.41 1.24 (1.13-1.36) 3.50 x 10-06 
 r2 = 0.68  Replication 0.36  0.40 1.18 (1.02-1.35) .02 
   Joint - - 1.22 (1.13-1.31) 2.69 x 10-07 
11q13.3 rs75915166 C/A GWAS 0.06 0.08 1.52 (1.25-1.83) 1.64 x 10-05 
   Replication 0.05 0.08 1.56 (1.19-2.04) .001 
   Joint - - 1.53 (1.31-1.79) 7.71 x 10-08 
 rs78540526 C/T GWAS 0.07 0.10 1.58 (1.34-1.87) 7.38 x 10-08 
 r2 = 0.63  Replication 0.06 0.10 1.68 (1.32-2.14) 2.45 x 10-05 
   Joint - - 1.61 (1.40-1.85) 1.06 x 10-11 
a For each locus the MBC effect estimates and association statistics for the lead FBC SNP are shown, followed by the estimates, correlation coefficient and 
association statistics for the correlated variant that was more strongly associated with MBC. 
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b Alleles are shown as major/minor allele based on control frequencies. 
c MBC P-values were derived from fixed-effects inverse variance-weighted meta-analysis (GWAS and Joint) and from multiple logistic regression, adjusted for 
study (Replication). All tests were two-sided. 




Table 4. Association between 313-SNP PRSs and male breast cancer risk. 
SNP weightsa Quintile No. of Controlsb 
Male Female 
No. of 
Cases OR (95% CI) P-value 
No. of 
Cases OR (95% CI) P-value 
Overall FBC 1st 533 124 1.00 (Ref)  165 1.00 (Ref)  
 2nd 532 227 1.83 (1.43-2.35) 1.92 x 10-06 251 1.52 (1.21-1.92) 3.35 x 10-04 
 3rd 533 244 1.97 (1.54-2.52) 8.07 x 10-08 340 2.06 (1.65-2.57) 1.53 x 10-10 
 4th 532 306 2.47 (1.94-3.15) 1.72 x 10-13 357 2.17 (1.74-2.70) 5.67 x 10-12 
 5th 533 479 3.86 (3.07-4.87) 2.08 x 10-30 558 3.38 (2.74-4.18) 1.17 x 10-29 
 Trendc 2,663 1,380 1.55 (1.45-1.66) 3.54 x 10-37 1,671 1.51 (1.42-1.61) 4.58 x 10-37 
ER-positive FBC 1st 533 120 1.00 (Ref)  167 1.00 (Ref)  
 2nd 532 229 1.91 (1.49-2.46) 4.37 x 10-07 254 1.52 (1.21-1.92) 3.17 x 10-04 
 3rd 533 243 2.03 (1.58-2.60) 2.97 x 10-08 312 1.87 (1.49-2.33) 3.95 x 10-08 
 4th 532 307 2.56 (2.01-3.27) 3.01 x 10-14 393 2.36 (1.90-2.93) 1.02 x 10-14 
 5th 533 481 4.01 (3.17-5.06) 1.91 x 10-31 545 3.26 (2.64-4.03) 4.10 x 10-28 
 Trendc 2,663 1,380 1.55 (1.45-1.66) 3.54 x 10-37 1,671 1.50 (1.41-1.60) 1.27 x 10-36 
ER-negative FBC 1st 533 175 1.00 (Ref)  201 1.00 (Ref)  
 2nd 532 204 1.17 (0.92-1.48) .20 244 1.22 (0.97-1.52) .08 
 3rd 533 280 1.60 (1.28-2.00) 3.85 x 10-05 354 1.76 (1.43-2.17) 1.39 x 10-07 
 4th 532 302 1.73 (1.39-2.16) 1.28 x 10-06 368 1.83 (1.49-2.26) 1.43 x 10-08 
 5th 533 419 2.39 (1.93-2.96) 1.06 x 10-15 504 2.51 (2.05-3.07) 6.56 x 10-19 
 Trendc 2,663 1,380 1.37 (1.29-1.47) 6.92 x 10-21 1,671 1.38 (1.29-1.47) 1.02 x 10-23 
a Weights for the 313 SNPs in the PRS for overall, ER-positive and ER-negative FBC were obtained from (20). 
b 2,663 males and females from the UK-58BC were used as UK population representative controls in the PRS analysis. 





Figure 1. Regional association plots for 6q25.1 (A), 10p12.31 (B) and 11q13.3 
(C) male breast cancer risk loci. Each point represents an individual SNP sorted 
on the x-axis by physical position based on NCBI build 37 of the human genome and 
plotted by -log10 P-value on the y-axis. Recombination rates, estimated using 
HapMap data, are plotted in blue. For each region, the published female breast 
cancer predisposition SNP is plotted as a circle, alongside the variant most strongly 
associated with male breast cancer, plotted as a diamond. In instances where there 
are multiple independent predisposition loci at the same genomic region, pairs of 
SNPs are grouped by colour. Lighter colours represent the GWAS P-value and 
darker colours the joint P-value for the top SNPs. All statistical tests were two-sided. 
 
Figure 2: Distributions of the 313-SNP PRS in 1,380 MBC cases, 1,671 FBC 
cases and 2,663 controls. PRS were standardised to mean = 0, SD = 1 using 2,663 




























Description of studies contributing to the discovery GWAS analysis 
Breast Cancer Now Male Breast Cancer Study (UK-BCN-MBCS) 
The UK-BCN-MBCS is a national population-based case-control study of male breast 
cancer in England and Wales that was established at the Institute of Cancer Research 
(ICR), London, in 2007 to investigate the aetiology of breast cancer in men and to 
illuminate, from a novel angle, aetiology in women. Potential cases were all men resident 
in England and Wales with invasive or in situ breast cancer diagnosed at ages 18-79 since 
1st January 2005. Cases were ascertained from regional cancer registries and directly 
from consultants. Cases undertook a structured interview with a study research nurse, who 
collected either a blood sample or a sputum sample for DNA extraction. Ninety-one 
percent of cases enrolled in the study provided a sample for DNA extraction. UK-BCN-
MBCS controls were from two sources – male non-blood relatives of cases, and male 
spouses of women taking part in the UK-GS (described below). Controls were stratum-
matched with cases, initially 1:1 and subsequently two controls per three cases, for 
economy. The study was approved by the South East Multicentre Research Ethics 
Committee. Following QC analysis, the discovery dataset used here for association 
analysis comprised 1,116 cases and 259 controls from UK-BCN-MBCS. 
 
City of Hope Male Breast Cancer Study (US-CoH) 
The US-CoH cases have been described elsewhere (1). Briefly, 83 cases were 
ascertained from state cancer registries in Utah and the surrounding intermountain states 
(Colorado, Idaho and Wyoming). A small number of additional cases were ascertained via 
an online male breast cancer support group (18 cases), referrals from physicians (four 
cases) and from family members (ten cases). The participants were enrolled under 
Institutional Review Board approval and all signed informed consent. The ten cases 
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referred by family members were from breast cancer families and the remaining cases 
were unselected for age or family history of breast cancer. The average age at diagnosis 
was 60 years with a range from 28 to 93 years. Following QC analysis, the discovery 
dataset used here for association analysis comprised 112 cases from US-CoH. 
 
University of Cambridge Male Breast Cancer Study (UK-UoC) 
The UK-UoC cases were obtained from a population-based study of male breast cancers 
that were diagnosed in areas covered by the East Anglia, Trent and the West Midlands 
cancer registries between 1991 and 2010 (2). Participants completed a detailed 
epidemiological questionnaire and provided a blood sample for genetic analysis. The study 
was approved by the National Research Ethics Service East of England – Cambridge 
South ethics committee. One hundred and sixty-five eligible patients were identified, of 
which 138 had samples available for genotyping in this study. Age at diagnosis of breast 
cancer of the 138 genotyped cases ranged from 29 to 87 years with a mean of 61 years. 
Following QC analysis, the discovery dataset used here for association analysis comprised 
129 cases from UK-UoC. 
 
University of Leeds Male Breast Cancer Study (UK-UoL) 
The UK-UoL cases were ascertained from a case control study of histologically confirmed 
male breast cancer conducted in the Yorkshire, Trent and North-West regions of the UK 
between 1983 and 1990 (3). The ages of the genotyped cases ranged from 41 to 80 
years, with mean 62 years, diagnosed between 1983 and 1990. Following QC analysis, 
the discovery dataset used here for association analysis comprised 23 cases from UK-
UoL. 
Generations Study (UK-GS) 
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The Generations Study (UK-GS) is a long-term prospective cohort study of breast cancer 
aetiology involving >113,000 women from the UK, recruited between 2003 and 2013 (4). 
The study cohort consists of women aged 16 years or older at entry who were identified 
from either a list of supporters of Breakthrough Breast Cancer (the charity who funded the 
study), by expression of interest via website and telephone lines when the study launched 
and finally by participant nomination of female friends and family. Upon registering to join 
the cohort, women were provided with a detailed epidemiological questionnaire and blood 
collection pack. Venepuncture was typically performed at the cohort members’ general 
practice surgery then blood samples were mailed to the study laboratory for recovery of 
buffy coat and plasma prior to long-term LN2 storage. The present study utilised genotype 
data from UK-GS controls that were generated using Oncoarray as part of the Breast 
Cancer Association Consortium (BCAC). Following QC analysis, the discovery dataset 
used for association analysis comprised 698 controls from UK-GS. 
 
1958 British Birth Cohort (UK-58BC) 
The 1958 British Birth Cohort is a cohort study of 17,415 UK individuals born in a single 
week of 1958 which has been extensively described (5) and for which a subset of healthy 
individuals was subject to genome-wide genotyping as part of the Wellcome Trust Case-
Control Consortium (WTCCC) (6). Access to individual-level genotype data is available by 
application to the WTCCC Data Access Committee. The WTCCC resource has been 
widely used to provide a geographically representative sample of SNP genotypes from UK 
individuals of predominantly European ancestry for genetic association studies. Following 
QC analysis, the discovery dataset used for association analysis comprised 1,367 male 
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Supplementary Table 1: Subjects for GWAS and validation 
 
 Source Status Number Source Age (years; mean, range) 
Years of diagnosis 
(cases) 
Discovery UK-BCN-MBCS Case 1210 Population of England and Wales  64 (23-87) 2003-2016  
  Control 264  64 (30-90) - 
 UK-UoL  Case 31 Population of Trent and Yorkshire, UK  62 (41-80) 1983-1990  
 UK-UoC Case 138 Population of West Midlands, Trent, and Eastern Cancer Registries  61 (29-87) 1991-2010  
 US-CoH Case 113 Population of USA  61 (28-93) 1963-2001  
 UK-58BC Control 2663 Population of England, Scotland and Wales  - - 
 UK-GS Control 698 Population of UK 54 (22-81) - 
Replication KConFab, Australia Case 72 Population of Australia and New Zealand  61 (31-87) 1977-2011 
  Control 70 Population of Australia and New Zealand  61 (37-92)  - 
 Peter MacCallum Cancer 
Centre, Australia Case 34 Hospital (PMCC familial cancer clinic) 66 (51-84)  1996-2010 
  Control -   - 
 The Finnish Male Breast 
Cancer Study, Finland Case 52 
Hospital-based series (Helsinki, Oulu, 
Vaasa and Kuopio)  61 (30-80)  1985-2011 
  Control 66 Adult blood donors from Finland  unknown - 
 University Hospital of 
Heraklion, Greece Case 29 
Hospital-based series (Athens and 
Heraklion) 58 (30-80) 1995-2012 
  Control 31 Adult blood donors from Heraklion, Crete, Greece  unknown 
 
 Sheba Medical Centre, 
Israel Case 33 Hospital-based series (Tel-Aviv) 65 (39-79)  2006-2011 
  Control 37 Hospital-based (unrelated healthy visitors; Tel-Aviv) 66 (39-82)  - 
 ISPO, Florence, Italy Case 80 Population of Tuscany 65 (35-87)  1990-2011 
  Control 89 Population of Tuscany 58 (43-65)  - 
 Sapienza University of 
Rome, Italy Case 32 Hospital-based series (Rome) 61 (22-79)  1986-2010 
  Control 33 Hospital-based series (Rome) 60 (55-64)  - 
 Erasmus MC, The 
Netherlands Case 51 
Breast cancer families from the South 
West of the Netherlands 57 (28-86)  1964-2009 
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  Control 49 Males from CF families who were spouses of at risk individuals 57 (28-86)  - 
 Institute of Oncology 
Ljubljana, Slovenia Case 34 Population of Slovenia 56 (17-86)  1970-2010 
  Control 45 Population of Slovenia 35 (18-60)  - 
 
Santiago and Vigo 
University Hospitals, 
Galicia, Spain 
Case 2 Population of Galicia, Spain 68 (49-88) 2000-2010 
  Control 9 Population of Galicia, Spain 68 (49-88) - 
 Lund University, Sweden Case 46 Hospital (Lund University Hospital) 63 (26-82)  1978-2010 
  Control 39 Spouses of cancer patients who had no history of cancer 63 (44-77)  - 
 BCN-MBCS, UK Case 345 Population of England and Wales  64 (37-78)  2009-2011 




Supplementary Table 2: Sensitivity of MBC predisposition SNP ORs to inclusion of 
US-CoH cases. 
 
 With US-CoH cases US-CoH cases omitted 
SNP OR (95% CI) P-value OR (95% CI) P-value 
rs9371545 1.61 (1.34-1.94) 6.59 x 10-07 1.63 (1.34-1.98) 1.11 x 10-06 
rs3757322 1.20 (1.08-1.34) 6.24 x 10-04 1.18 (1.05-1.31) 0.004 
rs146723925 1.21 (1.09-1.34) 4.43 x 10-04 1.19 (1.06-1.32) 0.002 
rs9397437 1.59 (1.32-1.92) 1.29 x 10-06 1.60 (1.31-1.94) 3.00 x 10-06 
rs9383938 1.54 (1.29-1.84) 1.99 x 10-06 1.54 (1.28-1.85) 5.75 x 10-06 
rs7072776 1.14 (1.02-1.27) 0.02 1.20 (1.00-1.27) 0.04 
rs2183271 1.22 (1.10-1.36) 1.37 x 10-04 1.21 (1.09-1.35) 4.88 x 10-04 
rs75915166 1.58 (1.27-1.97) 3.41 x 10-05 1.63 (1.03-2.05) 2.19 x 10-05 
rs78540526 1.68 (1.39-2.04) 1.47 x 10-07 1.76 (1.44-2.15) 4.26 x 10-08 
rs554219 1.43 (1.23-1.67) 4.06 x 10-06 1.47 (1.25-1.72) 2.11 x 10-06 
 
 
Supplementary Table 3: Sensitivity of MBC predisposition SNP ORs to inclusion of 
female UK-GS and UK-58BC controls. 
 
 All controls  No female controls 
SNP OR (95% CI) P-value OR (95% CI) P-value 
rs9371545 1.60 (1.36-1.89) 1.63 x 10-08 1.58 (1.31-1.89) 1.13 x 10-06 
rs3757322 1.23 (1.12-1.35) 1.11 x 10-05 1.22 (1.10-1.36) 2.06 x 10-04 
rs146723925 1.23 (1.13-1.35) 7.73 x 10-06 1.21 (1.09-1.35) 3.53 x 10-04 
rs9397437 1.58 (1.34-1.87) 4.22 x 10-08 1.54 (1.28-1.84) 4.66 x 10-06 
rs9383938 1.60 (1.36-1.89) 1.63 x 10-08 1.53 (1.29-1.82) 1.65 x 10-06 
rs7072776 1.17 (1.06-1.29) 0.002 1.22 (1.09-1.37) 4.27 x 10-04 
rs2183271 1.24 (1.13-1.36) 3.50 x 10-06 1.28 (1.15-1.42) 5.06 x 10-06 
rs75915166 1.52 (1.25-1.83) 1.64 x 10-05 1.49 (1.21-1.84) 1.92 x 10-04 
rs78540526 1.58 (1.34-1.87) 7.38 x 10-08 1.56 (1.30-1.88) 2.76 x 10-06 




Supplementary Table 4: Association analysis of loci that attained genome-wide significance (P-value ≤ 5 x 10-08) or promising 
signals of association (P-value ≤ 1 x 10-06) in combined analysis of three GWAS datasets and an independent validation cohort. 
 
Locusa  MAFb Info OR (95% CI) P-valuec P-hetd BFDPe  
rs3757322 GWAS 1 0.33 | 0.38 1 1.20 (1.08-1.34) 6.24 x 10-04   
6q25.1 GWAS 2 0.32 | 0.37 1 1.27 (1.00-1.62) 0.05   
T/G GWAS 3 0.28 | 0.35 1 1.42 (1.04-1.95) 0.03   
151942194 Combined   1.23 (1.12-1.35) 1.11 x 10-05 0.58  
 Validation 0.33 | 0.39  1.32 (1.15-1.52) 9.53 x 10-05   
 Overall (Fixed Effects)   1.26 (1.16-1.36) 6.23 x 10-09 0.62 8.20 x 10-04 
rs146723925f GWAS 1 0.35 | 0.4 0.984 1.21 (1.09-1.34) 4.20 x 10-04   
6q25.1 GWAS 2 0.33 | 0.4 0.991 1.31 (1.03-1.66) 0.03   
GAA/G GWAS 3 0.31 | 0.36 0.988 1.34 (0.98-1.84) 0.07   
151946173 Combined   1.23 (1.13-1.35) 7.73 x 10-06 0.73 0.54 
rs9397437 GWAS 1 0.07 | 0.1 0.994 1.59 (1.32-1.92) 1.30 x 10-06   
6q25.1 GWAS 2 0.07 | 0.1 1 1.58 (1.03-2.42) 0.03   
G/A GWAS 3 0.05 | 0.08 1 1.53 (0.87-2.69) 0.14   
151952332 Combined   1.58 (1.34-1.87) 4.22 x 10-08 0.99  
 Validation 0.07 | 0.1  1.33 (1.05-1.69) 0.02   
 Overall (Fixed Effects)   1.50 (1.31-1.71) 5.29 x 10-09 0.70 0.009 
rs9371545f GWAS 1 0.07 | 0.11 0.974 1.61 (1.34-1.94) 6.56 x 10-07   
6q25.1 GWAS 2 0.07 | 0.11 0.996 1.63 (1.07-2.48) 0.02   
G/A GWAS 3 0.05 | 0.08 0.982 1.50 (0.85-2.64) 0.16   
151969740 Combined   1.60 (1.36-1.89) 1.63 x 10-08 0.97 0.26 
rs9383938 GWAS 1 0.08 | 0.11 0.998 1.54 (1.29-1.84) 1.99 x 10-06   
6q25.1 GWAS 2 0.08 | 0.12 1 1.69 (1.13-2.53) 0.01   
G/T GWAS 3 0.06 | 0.09 1 1.57 (0.93-2.66) 0.09   
151987357 Combined   1.60 (1.36-1.89) 1.63 x 10-08 0.91  
 Validation 0.09 | 0.11  1.30 (1.04-1.63) 0.02   
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 Overall (Fixed Effects)   1.47 (1.30-1.67) 2.93 x 10-09 0.58 0.01 
rs2183271 GWAS 1 0.36 | 0.41 1 1.22 (1.1-1.36) 1.37 x 10-04   
10p12.31 GWAS 2 0.37 | 0.4 1 1.15 (0.91-1.46) 0.26   
T/C GWAS 3 0.32 | 0.42 0.971 1.55 (1.15-2.08) 0.004   
21957229 Combined   1.24 (1.13-1.36) 3.50 x 10-06 0.27  
 Validation 0.36 | 0.4  1.18 (1.02-1.35) 0.02   
 Overall (Fixed Effects)   1.22 (1.13-1.31) 2.69 x 10-07 0.39 0.006 
rs7072776 GWAS 1 0.27 | 0.3 1 1.14 (1.02-1.27) 0.02   
10p12.31 GWAS 2 0.28 | 0.32 1 1.22 (0.95-1.56) 0.12   
G/A GWAS 3 0.25 | 0.31 1 1.37 (1-1.87) 0.05   
22032942 Combined   1.17 (1.06-1.29) 0.002 0.52  
 Validation 0.28 | 0.31  1.15 (0.99-1.33) 0.06   
 Overall (Fixed Effects)   1.16 (1.07-1.26) 2.46 x 10-04 0.72 0.93 
rs78540526 GWAS 1 0.07 | 0.1 0.97 1.69 (1.39-2.05) 1.07 x 10-07   
11q13.3 GWAS 2 0.08 | 0.1 0.995 1.33 (0.89-2.00) 0.17   
C/T GWAS 3 0.07 | 0.08 1 1.25 (0.72-2.18) 0.42   
69331418 Combined   1.58 (1.34-1.87) 7.38 x 10-08 0.40  
 Validation 0.06 | 0.1  1.68 (1.32-2.14) 2.45 x 10-05   
 Overall (Fixed Effects)   1.61 (1.4-1.85) 1.06 x 10-11 0.57 0.001 
rs554219 GWAS 1 0.12 | 0.16 0.997 1.43 (1.23-1.67) 4.06 x 10-06   
11q13.3 GWAS 2 0.13 | 0.17 1 1.35 (0.97-1.87) 0.09   
C/G GWAS 3 0.11 | 0.15 0.999 1.45 (0.94-2.25) 0.07   
69331642 Combined   1.42 (1.24-1.62) 1.86 x 10-07 0.94  
 Validation 0.11 | 0.16  1.52 (1.25-1.84) 2.65 x 10-05   
 Overall (Fixed Effects)   1.45 (1.3-1.62) 2.86 x 10-11 0.94 2.77 x 10-04 
rs75915166 GWAS 1 0.06 | 0.08 0.941 1.6 (1.28-1.98) 2.59 x 10-05   
11q13.3 GWAS 2 0.06 | 0.07 1 1.27 (0.79-2.04) 0.32   
C/A GWAS 3 0.05 | 0.06 1 1.27 (0.70-2.58) 0.38   
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69379161 Combined   1.52 (1.25-1.83) 1.64 x 10-05 0.64  
 Validation 0.05 | 0.08  1.56 (1.19-2.04) 0.001   
 Overall (Fixed Effects)   1.53 (1.31-1.79) 7.71 x 10-08 0.82 0.32 
rs1022979g GWAS 1 0.17 | 0.23 0.998 1.55 (1.36-1.76) 3.82 x 10-11   
14q24.1 GWAS 2 0.16 | 0.26 0.999 1.81 (1.36-2.41) 4.86 x 10-05   
T/A GWAS 3 0.15 | 0.24 0.999 1.75 (1.22-2.52) 0.003   
68624639 Combined   1.60 (1.43-1.79) 1.53 x 10-16 0.55 4.63 x 10-08 
rs4407020 GWAS 1 0.22 | 0.27 1 1.29 (1.15-1.45) 2.52 x 10-05   
15q24 GWAS 2 0.21 | 0.28 0.905 1.60 (1.20-2.13) 0.001   
T/G GWAS 3 0.24 | 0.26 0.987 1.10 (0.79-1.54) 0.56   
70818373 Combined   1.31 (1.18-1.45) 4.51 x 10-07 0.23  
 Validation 0.24 | 0.24  0.93 (0.78-1.10) 0.39   
 Overall (Fixed Effects)   1.19 (1.09-1.31) 1.02 x 10-04 2.85 x 10-03 0.94 
rs35850695g GWAS 1 0.26 | 0.33 0.989 1.44 (1.29-1.62) 2.11 x 10-10   
16q12.1 GWAS 2 0.26 | 0.31 1 1.27 (0.99-1.63) 0.06   
G/A GWAS 3 0.27 | 0.33 0.996 1.29 (0.96-1.72) 0.09   
52574343 Combined   1.40 (1.27-1.54) 1.57 x 10-11 0.54 1.47 x 10-05 
a SNP alleles presented as reference / effect. 
b MAFs are presented as control MAF | case MAF. 
c All tests were two-sided. 
d P-value for Cochran’s Q-test for heterogeneity between the GWAS datasets and the validation dataset. 
e Bayesian false discovery probabilities for each association, assuming a maximum likely OR of 1.2 and a prior of 0.1%; the BFDP noteworthiness threshold was 0.8. 
f SNP rs9371545 failed assay design for replication genotyping therefore validation analysis was based on the next most significant correlated SNP that passed assay design, rs9383938 (r2 with rs9371545 
= 0.83).  





Supplementary Table 6: Comparison of effect estimates of FBC SNPs for male and female breast cancer. Differences are 
shown for overall FBC, ER-positive FBC and ER-negative FBC. 
 
 
     Overall FBC ER+ FBC ER- FBC 
Cytoband SNP Alleles OR MBC P MBC OR FBCa P Diffb P FDR OR ER+a P Diffb P FDR OR ER-a P Diffb P FDR 
1p36.22 rs616488 A/G 0.87 (0.80-0.96) 4.93E-03 0.94 (0.93-0.96) 0.07 0.38 0.96 (0.94-0.98) 0.03 0.19 0.89 (0.86-0.92) 0.62 0.88 
1p36.13 rs2992756 C/T 1.16 (1.06-1.27) 1.22E-03 1.06 (1.04-1.08) 0.06 0.34 1.07 (1.05-1.09) 0.09 0.39 1.03 (1.00-1.07) 0.01 0.12 
1p34.2 rs4233486 T/C 1.12 (1.02-1.23) 0.02 0.97 (0.95-0.98) 3.27E-03 0.09 0.97 (0.95-0.99) 3.27E-03 0.05 0.97 (0.94-1.00) 4.28E-03 0.05 
1p34.2 rs79724016 T/G 0.88 (0.67-1.15) 0.34 0.93 (0.88-0.97) 0.7 0.87 0.91 (0.86-0.96) 0.81 0.91 0.89 (0.98-1.07) 0.94 0.99 
1p34.1 rs1707302 G/A 0.99 (0.91-1.09) 0.91 0.96 (0.95-0.98) 0.48 0.78 0.96 (0.94-0.98) 0.49 0.77 1.01 (0.98-1.04) 0.66 0.88 
1p32.3 rs140850326 I*/C 0.98 (0.89-1.07) 0.6 0.97 (0.95-0.99) 0.84 0.91 0.97 (0.95-0.99) 0.84 0.91 0.96 (0.93-0.99) 0.69 0.88 
1p22.3 rs17426269 G/A 1.05 (0.93-1.18) 0.47 1.05 (1.02-1.07) 1 1 1.06 (1.03-1.09) 0.88 0.92 1.04 (0.99-1.08) 0.89 0.95 
1p13.2 rs11552449 C/T 1.13 (1.01-1.27) 0.03 1.04 (1.01-1.06) 0.16 0.49 1.04 (1.01-1.06) 0.16 0.48 1.04 (1.00-1.08) 0.17 0.59 
1p12 rs7529522 T/C 1.02 (0.92-1.13) 0.73 1.06 (1.04-1.08) 0.47 0.77 1.07 (1.04-1.09) 0.38 0.72 1.05 (1.02-1.09) 0.6 0.88 
1p11.2 rs11249433 A/G 1.01 (0.92-1.10) 0.85 1.11 (1.09-1.13) 0.05 0.31 1.14 (1.12-1.16) 0.01 0.13 1.02 (0.99-1.06) 0.84 0.94 
1q21.1 rs12405132 C/T 0.98 (0.90-1.08) 0.75 0.97 (0.95-0.99) 0.82 0.91 0.97 (0.95-0.99) 0.82 0.91 1.00 (0.96-1.03) 0.68 0.88 
1q21.2 rs12048493 A/C 1.08 (0.98-1.18) 0.12 1.04 (1.02-1.06) 0.46 0.76 1.04 (1.02-1.07) 0.46 0.75 1.05 (1.02-1.09) 0.59 0.88 
1q22 rs4971059 G/A 1.04 (0.95-1.14) 0.34 1.05 (1.03-1.07) 0.84 0.91 1.06 (1.04-1.09) 0.69 0.86 1.03 (1.00-1.07) 0.84 0.94 
1q32.1 rs35383942 C/T 1.19 (0.99-1.43) 0.06 1.12 (1.08-1.17) 0.53 0.8 1.10 (1.05-1.15) 0.42 0.72 1.15 (1.08-1.23) 0.73 0.89 
1q32.1 rs6678914 G/A 1.03 (0.94-1.13) 0.5 1.00 (0.99-1.02) 0.53 0.8 1.02 (1.00-1.04) 0.84 0.91 0.94 (0.91-0.97) 0.06 0.36 
1q32.19 rs4951011 A/G 0.99 (0.88-1.12) 0.85 1.04 (1.02-1.07) 0.42 0.72 1.03 (1.01-1.06) 0.52 0.77 1.07 (1.02-1.11) 0.23 0.64 
1q32.1 rs4245739 A/C 0.94 (0.85-1.03) 0.18 1.02 (1.00-1.04) 0.12 0.41 1.00 (0.98-1.02) 0.24 0.58 1.12 (1.09-1.17) 9.87E-04 0.02 
1q41 rs11117758 G/A 1.08 (0.97-1.21) 0.15 0.95 (0.93-0.97) 0.02 0.17 0.94 (0.92-0.96) 0.01 0.13 0.98 (0.95-1.02) 0.09 0.43 
1q43 rs72755295 A/G 0.88 (0.66-1.16) 0.37 1.15 (1.09-1.20) 0.07 0.38 1.16 (1.10-1.23) 0.06 0.35 1.09 (1.00-1.19) 0.16 0.57 
2p25.1 rs113577745 C/G 1.01 (0.87-1.17) 0.93 1.08 (1.05-1.11) 0.39 0.72 1.08 (1.04-1.10) 0.39 0.72 1.06 (1.01-1.12) 0.55 0.87 
2p24.1 rs12710696 C/T 0.87 (0.79-0.95) 2.76E-03 1.03 (1.01-1.04) 7.75E-04 0.03 1.01 (0.99-1.04) 2.99E-03 0.05 1.04 (1.00-1.07) 7.81E-04 0.02 
2p23.3 rs6725517 A/G 0.91 (0.83-0.99) 0.03 0.96 (0.94-0.98) 0.27 0.61 0.97 (0.95-0.99) 0.18 0.48 0.93 (0.90-0.96) 0.66 0.88 
2p23.2 rs4577244 C/T 1.00 (0.90-1.11) 0.98 1.01 (0.99-1.03) 0.86 0.91 1.05 (1.02-1.07) 0.38 0.72 0.93 (0.89-0.96) 0.21 0.63 
2q13 rs71801447 CTTATGTT/C 1.00 (0.84-1.20) 0.96 1.09 (1.05-1.13) 0.34 0.7 1.09 (1.05-1.13) 0.34 0.7 1.05 (0.99-1.12) 0.6 0.88 
2q14.1 rs4849887 C/T 0.96 (0.82-1.11) 0.55 0.91 (0.88-0.94) 0.52 0.8 0.92 (0.89-0.96) 0.6 0.81 0.85 (0.81-0.90) 0.15 0.55 
2q31.1 rs2016394 G/A 1.07 (0.98-1.17) 0.12 0.95 (0.94-0.97) 0.01 0.1 0.94 (0.92-0.96) 5.00E-03 0.07 1.00 (0.97-1.03) 0.15 0.55 
2q31.1 rs1550623 A/G 1.00 (0.89-1.12) 0.94 0.95 (0.93-0.98) 0.4 0.72 0.94 (0.91-0.97) 0.32 0.68 1.00 (0.95-1.04) 1 1 
2q33.1 rs1830298 T/C 1.09 (0.98-1.20) 0.1 1.06 (1.04-1.08) 0.61 0.84 1.05 (1.03-1.08) 0.5 0.77 1.08 (1.04-1.12) 0.87 0.94 
2q35 rs4442975  G/T 0.92 (0.85-1.01) 0.07 0.89 (0.87-0.90) 0.43 0.73 0.87 (0.85-0.88) 0.18 0.48 0.94 (0.92-0.98) 0.61 0.88 
2q35 rs34005590 C/A 0.98 (0.80-1.20) 0.83 0.82 (0.79-0.86) 0.09 0.38 0.80 (0.76-0.84) 0.06 0.33 0.98 (0.91-1.05) 1 1 
2q35 rs16857609 C/T 1.12 (1.01-1.23) 0.02 1.06 (1.04-1.09) 0.3 0.65 1.07 (1.04-1.08) 0.4 0.72 1.07 (1.03-1.10) 0.42 0.77 
2q36.3 rs12479355 A/G 0.90 (0.81-1.01) 0.06 0.96 (0.94-0.98) 0.24 0.59 0.96 (0.93-0.98) 0.25 0.59 1.00 (0.96-1.04) 0.07 0.36 
3p26.1 rs6762644 A/G 0.98 (0.89-1.07) 0.58 1.05 (1.03-1.07) 0.17 0.5 1.06 (1.04-1.08) 0.12 0.45 1.04 (1.01-1.08) 0.25 0.64 
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     Overall FBC ER+ FBC ER- FBC 
Cytoband SNP Alleles OR MBC P MBC OR FBCa P Diffb P FDR OR ER+a P Diffb P FDR OR ER-a P Diffb P FDR 
3p24.1 rs4973768 C/T 1.12 (1.03-1.23) 8.84E-03 1.11 (1.09-1.13) 0.84 0.91 1.12 (1.10-1.14) 1 1 1.04 (1.01-1.07) 0.1 0.45 
3p.24.1 rs12493607 G/C 1.03 (0.94-1.13) 0.5 1.05 (1.03-1.07) 0.69 0.86 1.06 (1.04-1.08) 0.55 0.77 1.00 (0.96-1.03) 0.56 0.88 
3p21.31 rs6796502 G/A 1.05 (0.91-1.21) 0.48 0.92 (0.89-0.95) 0.08 0.38 0.92 (0.89-0.95) 0.08 0.39 0.92 (0.87-0.97) 0.09 0.43 
3p14.1 rs1053338 A/G 1.11 (0.98-1.27) 0.11 1.05 (1.02-1.07) 0.39 0.72 1.03 (1.01-1.06) 0.24 0.59 1.03 (0.99-1.08) 0.26 0.66 
3p13 rs6805189 T/C 1.02 (0.94-1.12) 0.59 0.97 (0.95-0.99) 0.24 0.59 0.96 (0.94-0.98) 0.16 0.48 1.00 (0.97-1.03) 0.66 0.88 
3p12.1 rs13066793 A/G 1.28 (1.08-1.51) 5.24E-03 0.94 (0.91-0.97) 4.68E-04 0.03 0.93 (0.89-0.96) 3.60E-04 0.02 0.96 (0.91-1.02) 1.55E-03 0.03 
3p12.1 rs9833888 G/T 1.15 (1.04-1.28) 6.62E-03 1.06 (1.04-1.08) 0.12 0.41 1.07 (1.04-1.09) 0.18 0.48 1.01 (0.98-1.05) 0.02 0.12 
3q23 rs34207738 CTT/C 1.03 (0.94-1.13) 0.49 1.06 (1.04-1.08) 0.55 0.8 1.06 (1.04-1.08) 0.55 0.77 1.03 (1.00-1.07) 1 1 
3q26.31 rs58058861 G/A 1.09 (0.98-1.21) 0.12 1.06 (1.04-1.09) 0.61 0.84 1.07 (1.04-1.10) 0.74 0.9 1.00 (0.96-1.04) 0.14 0.55 
4p14 rs6815814 A/C 1.04 (0.93-1.16) 0.48 1.06 (1.04-1.08) 0.74 0.9 1.05 (1.03-1.08) 0.87 0.92 1.06 (1.02-1.10) 0.75 0.9 
4q21.23 4:84370124 TA/TAA 1.05 (0.95-1.15) 0.33 1.04 (1.02-1.05) 0.85 0.91 1.04 (1.01-1.06) 0.86 0.91 1.03 (1.00-1.06) 0.72 0.89 
4q22.1 rs10022462 C/T 1.03 (0.95-1.13) 0.47 1.04 (1.02-1.06) 0.82 0.91 1.04 (1.02-1.06) 0.82 0.91 1.01 (0.98-1.05) 0.66 0.88 
4q24 rs9790517 C/T 1.13 (1.02-1.27) 0.02 1.04 (1.01-1.06) 0.13 0.42 1.05 (1.03-1.08) 0.17 0.48 0.98 (0.94-1.02) 0.01 0.1 
4q28.1 rs77528541 G/T 0.86 (0.76-0.98) 0.03 0.95 (0.92-0.97) 0.13 0.42 0.94 (0.92-0.97) 0.16 0.48 0.94 (0.90-0.99) 0.18 0.59 
4q34.1 rs6828523 C/A 0.82 (0.72-0.95) 7.30E-03 0.91 (0.88-0.93) 0.13 0.42 0.88 (0.85-0.91) 0.3 0.67 1.00 (0.95-1.05) 5.40E-03 0.06 
5p15.33 rs116095464 T/C 1.11 (0.92-1.35) 0.28 1.06 (1.02-1.10) 0.64 0.86 1.07 (1.02-1.12) 0.71 0.88 1.03 (0.96-1.11) 0.46 0.79 
5p15.33 rs10069690 C/T 0.98 (0.89-1.08) 0.66 1.06 (1.04-1.08) 0.12 0.41 1.02 (1.00-1.05) 0.43 0.72 1.19 (1.14-1.23) 3.08E-04 7.57E-03 
5p15.33 rs3215401 A/AG 1.10 (1.00-1.21) 0.06 0.93 (0.91-0.95) 7.63E-04 0.03 0.95 (0.93-0.97) 3.26E-03 0.05 0.88 (0.85-0.91) 1.62E-05 9.27E-04 
5p15.1 rs13162653 G/T 1.00 (0.91-1.09) 0.97 0.99 (0.97-1.01) 0.84 0.91 0.99 (0.97-1.01) 0.84 0.91 0.98 (0.95-1.01) 0.69 0.88 
5p13.3 rs2012709 C/T 1.02 (0.93-1.11) 0.66 1.02 (1.00-1.04) 1 1 1.03 (1.01-1.05) 0.84 0.91 0.98 (0.95-1.01) 0.42 0.77 
5p12 rs10941679 A/G 1.27 (1.15-1.40) 3.03E-06 1.15 (1.13-1.18) 0.05 0.31 1.18 (1.16-1.21) 0.15 0.48 1.03 (1.00-1.07) 7.37E-05 2.53E-03 
5q11.1 rs72749841 T/C 1.01 (0.88-1.17) 0.84 0.93 (0.91-0.96) 0.25 0.6 0.94 (0.90-0.97) 0.33 0.68 0.99 (0.94-1.04) 0.79 0.94 
5q11.1 rs35951924 A/AT 1.02 (0.92-1.13) 0.68 0.95 (0.93-0.97) 0.19 0.53 0.95 (0.93-0.97) 0.19 0.48 0.96 (0.93-1.00) 0.27 0.67 
5q11.2 rs62355902 A/T 0.99 (0.87-1.11) 0.82 1.18 (1.15-1.21) 0.01 0.1 1.22 (1.19-1.25) 1.86E-03 0.05 1.06 (1.02-1.11) 0.32 0.71 
5q11.2 rs10472076 T/C 1.06 (0.97-1.16) 0.2 1.03 (1.01-1.04) 0.54 0.8 1.03 (1.01-1.05) 0.54 0.77 1.03 (1.00-1.07) 0.55 0.87 
5q11.2 rs1353747 T/G 0.92 (0.79-1.06) 0.24 0.96 (0.93-0.99) 0.59 0.83 0.95 (0.92-0.98) 0.69 0.86 0.98 (0.92-1.03) 0.45 0.78 
5q14.2 rs7707921 A/T 1.05 (0.95-1.17) 0.34 0.96 (0.94-0.98) 0.09 0.38 0.95 (0.93-0.97) 0.06 0.33 0.97 (0.93-1.00) 0.15 0.55 
5q14.39 rs10474352 C/T 0.93 (0.83-1.06) 0.29 0.94 (0.92-0.97) 0.86 0.91 0.94 (0.91-0.96) 0.86 0.91 0.98 (0.94-1.03) 0.4 0.77 
5q22.1 rs6882649 T/G 0.92 (0.83-1.01) 0.08 0.97 (0.95-0.99) 0.32 0.66 0.97 (0.95-0.99) 0.32 0.68 0.98 (0.94-1.01) 0.26 0.66 
5q31.1 rs6596100 C/T 0.86 (0.77-0.96) 5.29E-03 0.94 (0.92-0.96) 0.12 0.41 0.94 (0.92-0.96) 0.12 0.45 0.95 (0.92-0.99) 0.09 0.43 
5q33.3 rs1432679 T/C 0.95 (0.87-1.04) 0.25 1.08 (1.06-1.10) 0.01 0.1 1.07 (1.05-1.10) 9.56E-03 0.12 1.08 (1.04-1.11) 8.64E-03 0.09 
5q35.1 rs4562056 G/T 0.95 (0.87-1.04) 0.29 1.05 (1.03-1.07) 0.03 0.21 1.06 (1.03-1.08) 0.02 0.17 1.02 (0.99-1.05) 0.13 0.55 
6p25.3 rs11242675 T/C 0.98 (0.89-1.07) 0.66 1.00 (0.98-1.02) 0.69 0.86 1.00 (0.98-1.02) 0.69 0.86 0.99 (0.96-1.02) 0.84 0.94 
6p24.3 rs9348512 C/A 1.08 (0.98-1.18) 0.12 1.00 (0.99-1.02) 0.12 0.41 1.00 (0.98-1.03) 0.13 0.45 1.01 (0.98-1.05) 0.2 0.6 
6p23 rs204247 A/G 0.99 (0.91-1.09) 0.9 1.04 (1.02-1.06) 0.26 0.6 1.04 (1.02-1.06) 0.26 0.6 1.00 (0.97-1.03) 0.83 0.94 
6p22.3 rs3819405 C/T 0.89 (0.81-0.98) 0.02 0.96 (0.94-0.97) 0.12 0.41 0.95 (0.93-0.97) 0.19 0.48 0.97 (0.94-1.00) 0.09 0.43 
6p22.3 rs2223621 C/T 1.04 (0.95-1.14) 0.36 1.04 (1.02-1.06) 1 1 1.03 (1.01-1.06) 0.84 0.91 1.02 (0.99-1.05) 0.69 0.88 
6p22.2 rs71557345 G/A 0.93 (0.80-1.09) 0.36 0.92 (0.88-0.96) 0.89 0.93 0.91 (0.87-0.96) 0.79 0.91 0.91 (0.84-0.98) 0.8 0.94 
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     Overall FBC ER+ FBC ER- FBC 
Cytoband SNP Alleles OR MBC P MBC OR FBCa P Diffb P FDR OR ER+a P Diffb P FDR OR ER-a P Diffb P FDR 
6p22.1 rs9257408 G/C 1.06 (0.97-1.16) 0.21 1.02 (1.00-1.04) 0.41 0.72 1.03  (1.02-1.05) 0.55 0.77 1.04  (1.02-1.07) 0.7 0.88 
6q14.1 rs12207986 A/G 1.03 (0.94-1.13) 0.49 0.97 (0.95-0.98) 0.21 0.55 0.97 (0.95-0.99) 0.21 0.53 0.96 (0.93-0.99) 0.15 0.55 
6q14.1 rs17529111 T/C 1.14 (1.02-1.27) 0.02 1.02 (1.00-1.04) 0.05 0.31 1.01 (0.98-1.03) 0.04 0.27 1.06 (1.02-1.10) 0.23 0.64 
6q23.1 rs6569648 T/C 0.99 (0.89-1.10) 0.81 0.94 (0.92-0.96) 0.35 0.7 0.95 (0.92-0.97) 0.47 0.76 0.94 (0.91-0.98) 0.36 0.77 
6q25.19 rs9485372   G/A 1.04 (0.93-1.17) 0.48 0.96 (0.93-0.98) 0.18 0.52 0.95 (0.92-0.97) 0.13 0.45 0.99 (0.95-1.03) 0.42 0.77 
6q25 rs3757322 T/G 1.23 (1.12-1.35) 1.11E-05 1.08 (1.06-1.10) 0.01 0.1 1.06 (1.04-1.08) 2.29E-03 0.05 1.14 (1.10-1.18) 0.14 0.55 
6q25 rs9397437 G/A 1.58 (1.34-1.87) 4.22E-08 1.17 (1.14-1.21) 4.15E-04 0.03 1.14 (1.10-1.18) 1.48E-04 9.52E-03 1.32 (1.25-1.4) 0.04 0.28 
6q25 rs2747652 C/T 0.87 (0.80-0.95) 2.72E-03 0.94 (0.92-0.96) 0.08 0.38 0.95 (0.93-0.97) 0.05 0.31 0.92 (0.89-0.95) 0.22 0.64 
7p15.3 rs7971 A/G 0.97 (0.88-1.06) 0.46 0.96 (0.94-0.98) 0.84 0.91 0.96 (0.94-0.98) 0.84 0.91 0.96 (0.93-0.99) 0.84 0.94 
7p15.1 rs17156577 T/C 1.01 (0.88-1.17) 0.85 1.05 (1.02-1.08) 0.59 0.83 1.05 (1.02-1.08) 0.59 0.8 1.05 (1.00-1.10) 0.6 0.88 
7q21.2 rs6964587 G/T 1.02 (0.93-1.11) 0.72 1.03 (1.02-1.05) 0.84 0.91 1.03 (1.01-1.05) 0.84 0.91 1.02 (0.98-1.05) 1 1 
7q21.3 rs17268829 T/C 1.04 (0.94-1.14) 0.45 1.05 (1.03-1.07) 0.86 0.91 1.06 (1.04-1.08) 0.72 0.88 1.02 (0.98-1.05) 0.73 0.89 
7q22.1 rs71559437 G/A 1.02 (0.90-1.16) 0.76 0.93 (0.91-0.96) 0.15 0.47 0.92 (0.89-0.95) 0.12 0.45 0.95 (0.90-1.00) 0.31 0.7 
7q32.3 rs4593472 C/T 0.95 (0.87-1.05) 0.32 0.97 (0.95-0.99) 0.65 0.86 0.97 (0.95-0.99) 0.65 0.86 0.97 (0.93-1.00) 0.68 0.88 
7q34 rs11977670 G/A 1.04 (0.95-1.14) 0.37 1.06 (1.04-1.08) 0.69 0.86 1.06 (1.04-1.09) 0.69 0.86 1.02 (0.99-1.05) 0.69 0.88 
7q35 rs720475 G/A 1.05 (0.95-1.17) 0.32 0.96 (0.94-0.98) 0.09 0.38 0.96 (0.94-0.98) 0.09 0.39 1.00 (0.96-1.03) 0.38 0.77 
8p12 rs9693444 C/A 1.08 (0.98-1.18) 0.13 1.06 (1.04-1.08) 0.71 0.87 1.07 (1.05-1.10) 0.85 0.91 1.02 (0.98-1.05) 0.29 0.67 
8p11.23 rs13365225 A/G 1.02 (0.90-1.15) 0.81 0.91 (0.89-0.93) 0.08 0.38 0.91 (0.89-0.94) 0.08 0.39 0.90 (0.86-0.94) 0.07 0.36 
8q21.11 rs6472903 T/G 0.94 (0.84-1.05) 0.29 0.94 (0.92-0.96) 1 1 0.93 (0.91-0.96) 0.85 0.91 0.96 (0.92-1.00) 0.73 0.89 
8q21.11 rs2943559 A/G 1.19 (1.01-1.40) 0.04 1.10 (1.07-1.14) 0.35 0.7 1.10 (1.06-1.14) 0.36 0.72 1.10 (1.04-1.16) 0.37 0.77 
8q22.3 rs514192 T/A 1.16 (1.06-1.28) 2.29E-03 1.05 (1.03-1.07) 0.03 0.21 1.06 (1.03-1.08) 0.06 0.34 1.01 (0.98-1.05) 4.30E-03 0.05 
8q23.1 rs12546444 A/T 0.89 (0.76-1.03) 0.12 0.93 (0.91-0.96) 0.59 0.83 0.93 (0.89-0.96) 0.6 0.81 0.98 (0.93-1.03) 0.26 0.66 
8q23.3 rs13267382 G/A 1.02 (0.92-1.12) 0.74 1.03 (1.01-1.05) 0.86 0.91 1.04 (1.01-1.06) 0.72 0.88 1.02 (0.98-1.05) 1 1 
8q24.13 rs58847541 G/A 1.18 (1.04-1.33) 0.01 1.08 (1.05-1.10) 0.18 0.52 1.07 (1.04-1.10) 0.14 0.46 1.13 (1.08-1.18) 0.53 0.87 
8q24.21 rs13281615 A/G 1.06 (0.97-1.16) 0.21 1.11 (1.09-1.13) 0.32 0.66 1.11 (1.09-1.14) 0.32 0.68 1.07 (1.03-1.10) 0.85 0.94 
8q24.21 rs11780156 C/T 1.07 (0.95-1.20) 0.26 1.05 (1.03-1.08) 0.76 0.91 1.05 (1.02-1.08) 0.76 0.91 1.05 (1.01-1.10) 0.77 0.92 
9p21.3 rs1011970 G/T 1.11 (0.99-1.25) 0.08 1.07 (1.04-1.09) 0.54 0.8 1.06 (1.04-1.09) 0.44 0.73 1.05 (1.00-1.09) 0.38 0.77 
9q31.2 rs10759243 C/A 0.95 (0.86-1.05) 0.31 1.06 (1.04-1.08) 0.03 0.21 1.07 (1.05-1.10) 0.02 0.17 1.02 (0.99-1.06) 0.18 0.59 
9q31.2 rs10816625 A/G 0.85 (0.71-1.03) 0.09 1.11 (1.07-1.15) 4.40E-03 0.09 1.13 (1.08-1.17) 2.64E-03 0.05 1.07 (1.01-1.14) 0.02 0.13 
9q31.2 rs13294895 C/T 0.96 (0.85-1.08) 0.52 1.06 (1.03-1.08) 0.12 0.41 1.07 (1.05-1.10) 0.08 0.39 0.99 (0.95-1.04) 0.64 0.88 
9q31.2 rs676256 T/C 1.01 (0.92-1.11) 0.8 0.91 (0.90-0.93) 0.03 0.21 0.90 (0.88-0.92) 0.02 0.16 0.98 (0.94-1.01) 0.56 0.88 
9q33.1 rs1895062 A/G 1.07 (0.98-1.17) 0.16 0.94 (0.92-0.95) 0.01 0.1 0.94 (0.92-0.96) 5.00E-03 0.07 0.93 (0.90-0.96) 3.38E-03 0.05 
9q33.3 rs10760444 A/G 0.99 (0.90-1.08) 0.78 1.03 (1.02-1.05) 0.42 0.72 1.03 (1.01-1.05) 0.42 0.72 1.05 (1.02-1.08) 0.25 0.64 
9q34.2 rs8176636 I*/T 0.98 (0.87-1.09) 0.66 1.03 (1.01-1.06) 0.42 0.72 1.04 (1.01-1.06) 0.34 0.7 1.05 (1.01-1.09) 0.28 0.67 
10p15.1 rs2380205 C/T 1.01 (0.92-1.10) 0.89 0.98 (0.96-0.99) 0.54 0.8 0.98 (0.96-1.00) 0.54 0.77 0.97 (0.94-1.00) 0.42 0.77 
10p14 rs67958007 TG/T 1.04 (0.91-1.19) 0.56 1.09 (1.06-1.12) 0.5 0.8 1.09 (1.06-1.12) 0.5 0.77 1.08 (1.03-1.14) 0.6 0.88 
10p12.31 rs7072776 G/A 1.17 (1.06-1.29) 1.60E-03 1.05 (1.03-1.07) 0.03 0.21 1.07 (1.04-1.09) 0.09 0.39 0.99 (0.95-1.02) 2.21E-03 0.03 
10p12.31 rs11814448 A/C 0.84 (0.60-1.19) 0.32 1.12 (1.06-1.19) 0.1 0.41 1.15 (1.07-1.22) 0.07 0.38 1.04 (0.94-1.16) 0.23 0.64 
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Cytoband SNP Alleles OR MBC P MBC OR FBCa P Diffb P FDR OR ER+a P Diffb P FDR OR ER-a P Diffb P FDR 
10q21.2 rs10995201 A/G 0.85 (0.75-0.96) 0.01 0.90 (0.88-0.92) 0.38 0.72 0.89 (0.87-0.92) 0.48 0.76 0.93 (0.89-0.98) 0.18 0.59 
10q22.3 rs704010 C/T 1.04 (0.95-1.14) 0.42 1.07 (1.05-1.09) 0.55 0.8 1.08 (1.06-1.10) 0.42 0.72 1.06 (1.03-1.09) 0.69 0.88 
10q23.33 rs140936696 C/CAA 1.01 (0.90-1.13) 0.86 1.04 (1.02-1.07) 0.62 0.85 1.05 (1.02-1.07) 0.52 0.77 1.04 (0.99-1.08) 0.65 0.88 
10q25.2 rs7904519 A/G 1.02 (0.94-1.12) 0.61 1.03 (1.01-1.05) 0.82 0.91 1.02 (1.00-1.04) 1 1 1.08 (1.04-1.11) 0.21 0.63 
10q26.12 rs11199914 C/T 0.94 (0.86-1.04) 0.25 0.96 (0.94-0.98) 0.65 0.86 0.95 (0.93-0.97) 0.82 0.91 0.98 (0.95-1.02) 0.39 0.77 
10q26.13 rs2981578 T/C 1.08 (0.99-1.18) 0.07 1.23 (1.21-1.25) 3.99E-03 0.09 1.28 (1.26-1.31) 1.66E-04 9.52E-03 1.04 (1.00-1.07) 0.44 0.77 
10q26.13 rs35054928 G/GC 1.13 (1.03-1.23) 8.65E-03 1.27 (1.25-1.30) 0.01 0.1 1.34 (1.31-1.37) 4.61E-04 0.02 1.06 (1.03-1.10) 0.2 0.6 
10q26.13 rs45631563 A/T 0.81 (0.65-1.00) 0.05 0.81 (0.78-0.85) 1 1 0.77 (0.73-0.81) 0.66 0.86 0.93 (0.86-1.00) 0.25 0.64 
11p15 rs6597981 G/A 1.04 (0.95-1.14) 0.39 0.96 (0.94-0.97) 0.09 0.38 0.96 (0.94-0.98) 0.09 0.39 0.94 (0.91-0.97) 0.04 0.27 
11p15.5 rs3817198 T/C 1.07 (0.98-1.18) 0.15 1.05 (1.03-1.07) 0.68 0.86 1.05 (1.03-1.08) 0.68 0.86 1.02 (0.99-1.06) 0.31 0.7 
11q13.1 rs3903072 G/T 1.03 (0.94-1.12) 0.55 0.97 (0.95-0.99) 0.21 0.55 0.96 (0.94-0.98) 0.14 0.46 0.99 (0.96-1.02) 0.42 0.77 
11q13.3 rs554219 C/G 1.42 (1.24-1.62) 1.86E-07 1.21 (1.18-1.24) 0.02 0.17 1.27 (1.24-1.31) 0.11 0.45 0.98 (0.94-1.03) 2.96E-07 2.55E-05 
11q13.3 rs75915166 C/A 1.52 (1.25-1.83) 1.64E-05 1.28 (1.24-1.33) 0.09 0.38 1.35 (1.29-1.40) 0.25 0.59 0.99 (0.92-1.06) 5.73E-05 2.47E-03 
11q24.3 rs11820646 C/T 1.01 (0.92-1.11) 0.81 0.96 (0.94-0.98) 0.3 0.65 0.97 (0.95-0.99) 0.41 0.72 0.94 (0.91-0.97) 0.15 0.55 
12p13.1 rs12422552 G/C 1.05 (0.95-1.16) 0.33 1.06 (1.04-1.08) 0.86 0.91 1.05 (1.03-1.07) 1 1 1.04 (1.01-1.08) 0.86 0.94 
12p11.22 rs7297051 C/T 0.87 (0.78-0.97) 9.71E-03 0.89 (0.87-0.91) 0.69 0.86 0.90 (0.87-0.92) 0.56 0.78 0.87 (0.84-0.91) 1 1 
12q21.31 rs202049448 T/C 0.96 (0.87-1.06) 0.44 0.95 (0.93-0.97) 0.84 0.91 0.95 (0.93-0.97) 0.84 0.91 0.93 (0.90-0.96) 0.55 0.87 
12q22 rs17356907 A/G 0.96 (0.87-1.06) 0.4 0.91 (0.90-0.93) 0.29 0.65 0.92 (0.90-0.94) 0.41 0.72 0.94 (0.91-0.97) 0.69 0.88 
12q24.21 rs1292011 A/G 0.97 (0.89-1.06) 0.46 0.92 (0.90-0.94) 0.24 0.59 0.91 (0.89-0.92) 0.16 0.48 0.98 (0.95-1.01) 0.83 0.94 
12q24.31 rs206966 C/T 0.97 (0.86-1.1) 0.69 1.05 (1.02-1.07) 0.21 0.55 1.06 (1.03-1.09) 0.16 0.48 1.04 (1.00-1.09) 0.28 0.67 
13q13.1 rs11571833 A/T 1.82 (1.18-2.81) 6.70E-03 1.35 (1.23-1.48) 0.19 0.53 1.28 (1.15-1.42) 0.12 0.45 1.58 (1.35-1.84) 0.55 0.87 
13q22.1 rs6562760 G/A 1.01 (0.91-1.12) 0.88 0.95 (0.93-0.97) 0.26 0.6 0.95 (0.93-0.98) 0.26 0.59 0.92 (0.88-0.95) 0.11 0.46 
14q13.3 rs2236007 G/A 0.97 (0.88-1.09) 0.64 0.93 (0.91-0.95) 0.41 0.72 0.93 (0.91-0.96) 0.41 0.72 0.95 (0.91-0.99) 0.7 0.88 
14q24.1 rs2588809 C/T 1.59 (1.41-1.78) 4.58E-15 1.06 (1.03-1.08) 1.25E-10 2.15E-08 1.07 (1.04-1.10) 3.22E-10 5.55E-08 0.99 (0.95-1.03) 2.67E-13 4.58E-11 
14q24.1 rs999737 C/T 0.88 (0.79-0.97) 0.01 0.91 (0.89-0.93) 0.55 0.8 0.91 (0.88-0.93) 0.56 0.78 0.92 (0.89-0.96) 0.44 0.77 
14q32.11 rs941764 A/G 1.05 (0.96-1.15) 0.28 1.03 (1.02-1.05) 0.68 0.86 1.03 (1.01-1.06) 0.68 0.86 1.01 (0.98-1.04) 0.42 0.77 
14q32.12 rs11627032 T/C 0.92 (0.84-1.02) 0.12 0.96 (0.94-0.98) 0.37 0.72 0.96 (0.94-0.98) 0.37 0.72 0.95 (0.92-0.99) 0.51 0.86 
14q32.33 rs10623258 C/CTT 1.11 (1.02-1.22) 0.02 1.04 (1.02-1.06) 0.14 0.45 1.04 (1.02-1.06) 0.14 0.46 1.03 (1.00-1.06) 0.1 0.45 
15q26.19 rs2290203 G/A 0.93 (0.83-1.04) 0.2 0.94 (0.92-0.96) 0.86 0.91 0.94 (0.91-0.96) 0.86 0.91 0.96 (0.92-1.00) 0.61 0.88 
16q12.1 rs4784227 C/T 1.40 (1.27-1.54) 4.49E-11 1.23 (1.20-1.25) 0.01 0.1 1.25 (1.22-1.28) 0.03 0.19 1.14 (1.10-1.19) 1.05E-04 3.00E-03 
16q12.2 rs17817449 T/G 1.04 (0.95-1.14) 0.37 0.95 (0.93-0.96) 0.06 0.34 0.95 (0.93-0.97) 0.06 0.33 0.93 (0.90-0.96) 0.02 0.16 
16q12.2 rs11075995 T/A 1.02 (0.92-1.13) 0.7 1.03 (1.01-1.06) 0.86 0.91 1.02 (0.99-1.04) 1 1 1.07 (1.03-1.11) 0.39 0.77 
16q12.2 rs28539243 G/A 1.04 (0.95-1.13) 0.44 1.05 (1.03-1.07) 0.84 0.91 1.05 (1.03-1.07) 0.84 0.91 1.05 (1.01-1.08) 0.85 0.94 
16q13 rs2432539 G/A 1.07 (0.98-1.17) 0.12 1.03 (1.02-1.05) 0.4 0.72 1.04 (1.02-1.06) 0.54 0.77 1.02 (0.99-1.06) 0.31 0.7 
16q23.2 rs13329835 A/G 1.05 (0.95-1.17) 0.36 1.07 (1.05-1.09) 0.72 0.88 1.08 (1.05-1.11) 0.6 0.81 1.06 (1.02-1.10) 0.86 0.94 
16q24.2 rs4496150 C/A 1.02 (0.92-1.14) 0.64 0.96 (0.94-0.98) 0.26 0.6 0.96 (0.94-0.99) 0.26 0.59 0.96 (0.92-0.99) 0.29 0.67 
17q11.2  rs146699004 GGT/G 0.92 (0.83-1.02) 0.1 0.97 (0.95-0.99) 0.32 0.66 0.96 (0.94-0.99) 0.43 0.72 0.96 (0.93-0.98) 0.44 0.77 
17q21.2 rs72826962 C/T 1.22 (0.82-1.82) 0.32 1.20 (1.11-1.30) 0.94 0.97 1.20 (1.10-1.31) 0.94 0.96 1.13 (0.98-1.30) 0.72 0.89 
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     Overall FBC ER+ FBC ER- FBC 
Cytoband SNP Alleles OR MBC P MBC OR FBCa P Diffb P FDR OR ER+a P Diffb P FDR OR ER-a P Diffb P FDR 
17q21.31 rs2532263 G/A 1.00 (0.89-1.12) 0.97 0.95 (0.93-0.97) 0.4 0.72 0.95 (0.93-0.98) 0.4 0.72 0.95 (0.91-0.99) 0.42 0.77 
17q22 rs2787486 A/C 0.98 (0.89-1.08) 0.73 0.93 (0.91-0.94) 0.3 0.65 0.91 (0.89-0.93) 0.14 0.46 0.96 (0.93-1.00) 0.69 0.88 
17q25.3 rs745570 G/A 1.00 (0.92-1.10) 0.95 1.03 (1.01-1.05) 0.5 0.8 1.02 (1.00-1.04) 0.65 0.86 1.04 (1.01-1.07) 0.38 0.77 
18q11.2 rs527616 G/C 0.95 (0.86-1.04) 0.27 0.97 (0.95-0.98) 0.69 0.86 0.95 (0.94-0.97) 1 1 1.00 (0.97-1.03) 0.33 0.73 
18q11.2 rs1436904 T/G 1.02 (0.94-1.12) 0.58 0.95 (0.94-0.97) 0.09 0.38 0.94 (0.92-0.96) 0.06 0.33 0.99 (0.96-1.03) 0.5 0.85 
18q12.1 rs117618124 T/C 0.88 (0.71-1.09) 0.25 0.89 (0.85-0.92) 0.92 0.96 0.89 (0.85-0.94) 0.92 0.95 0.84 (0.77-0.91) 0.69 0.88 
18q12.3 rs6507583 A/G 0.82 (0.69-0.97) 0.02 0.92 (0.89-0.96) 0.2 0.55 0.90 (0.86-0.94) 0.31 0.67 0.97 (0.91-1.03) 0.07 0.38 
19p13.13 rs78269692 T/C 1.18 (0.97-1.44) 0.09 1.09 (1.04-1.13) 0.44 0.73 1.09 (1.04-1.14) 0.44 0.73 1.09 (1.02-1.17) 0.45 0.78 
19p13.12 rs2594714 G/A 0.90 (0.81-1.00) 0.06 0.97 (0.95-0.99) 0.17 0.5 0.97 (0.95-1.00) 0.17 0.48 1.00 (0.96-1.04) 0.07 0.36 
19p13.11 rs67397200 C/G 1.02 (0.93-1.13) 0.62 1.03 (1.01-1.05) 0.84 0.91 0.99 (0.97-1.01) 0.54 0.77 1.17 (1.13-1.21) 6.44E-03 0.07 
19p13.11 rs4808801 A/G 0.95 (0.86-1.04) 0.23 0.93 (0.91-0.95) 0.68 0.86 0.92 (0.91-0.94) 0.53 0.77 0.96 (0.93-0.99) 0.84 0.94 
19p13.11 rs2965183 G/A 0.98 (0.89-1.07) 0.66 1.04 (1.02-1.06) 0.24 0.59 1.04 (1.02-1.06) 0.24 0.58 1.05 (1.02-1.09) 0.18 0.59 
19q13.31 rs3760982 G/A 1.02 (0.93-1.11) 0.72 1.05 (1.03-1.07) 0.55 0.8 1.06 (1.04-1.08) 0.42 0.72 1.08 (1.05-1.12) 0.25 0.64 
19q13.22 rs71338792 A/AT 0.92 (0.83-1.03) 0.17 1.05 (1.03-1.07) 0.01 0.1 1.05 (1.03-1.08) 0.01 0.13 1.03 (0.99-1.07) 0.04 0.29 
20p12.3 rs16991615 G/A 1.02 (0.85-1.21) 0.86 1.10 (1.06-1.14) 0.43 0.73 1.10 (1.06-1.14) 0.43 0.72 1.10 (1.04-1.18) 0.44 0.77 
20q11.22 rs2284378 C/T 1.13 (1.03-1.24) 0.01 1.00 (0.98-1.02) 0.01 0.1 1.00 (0.97-1.02) 0.01 0.13 0.99 (0.95-1.02) 0.01 0.1 
20q13.13 rs6122906 A/G 1.09 (0.96-1.22) 0.18 1.05 (1.03-1.07) 0.57 0.82 1.04 (1.02-1.07) 0.47 0.76 1.08 (1.03-1.12) 0.89 0.96 
21q21.1 rs2823093 G/A 1.00 (0.90-1.11) 1 0.94 (0.92-0.96) 0.26 0.6 0.92 (0.91-0.94) 0.12 0.45 1.00 (0.96-1.04) 1 1 
22q12.1 rs17879961 A/G 0.88 (0.24-3.23) 0.85 1.26 (1.11-1.42) 0.59 0.83 1.39 (1.22-1.60) 0.49 0.77 0.86 (0.68-1.09) 0.97 1 
22q12.2 rs132390 T/C 1.42 (1.11-1.82) 4.71E-03 1.04 (0.99-1.09) 0.02 0.17 1.04 (0.98-1.09) 0.02 0.14 1.01 (0.92-1.09) 0.01 0.1 
22q13.1 rs738321 C/G 0.99 (0.90-1.08) 0.78 0.95 (0.93-0.97) 0.41 0.72 0.93 (0.91-0.95) 0.21 0.53 0.99 (0.96-1.02) 1 1 
22q13.19 chr22:39359355 I/D 1.10 (0.93-1.30) 0.28 1.10 (1.07-1.14) 1 1 1.11 (1.07-1.15) 0.92 0.95 1.09 (1.04-1.14) 0.92 0.97 
22q13.1 rs6001930 T/C 1.16 (1.00-1.34) 0.05 1.12 (1.09-1.16) 0.65 0.86 1.11 (1.08-1.15) 0.57 0.78 1.14 (1.08-1.19) 0.83 0.94 
22q13.2 rs73161324 C/T 1.16 (0.95-1.43) 0.15 1.06 (1.02-1.09) 0.38 0.72 1.04 (1.00-1.08) 0.29 0.65 1.10 (1.03-1.18) 0.62 0.88 
22q13.31 rs28512361 G/A 0.93 (0.80-1.08) 0.34 1.05 (1.02-1.08) 0.12 0.41 1.05 (1.02-1.08) 0.12 0.45 1.09 (1.04-1.14) 0.05 0.3 
a Effect estimates obtained from Michailidou et al. Nature 2017;551(7678):92-94. (8) 
 
b P-value for the significance of the differences between the MBC and FBC ORs. 
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Supplementary Table 7: Conditional analyses of SNPs at 6q25.1, 10p12.31 and 11q13.3. 
 
Cytoband Conditioning SNP SNP Alleles MAF Score X2 P-value 
6q25.1 rs9397437 rs3757322 T|G 0.327|0.377 14.05 1.78 x 10-04 
  rs9383938 G|T 0.079|0.111 2.51 0.11 
 rs3757322 rs9397437 G|A 0.070|0.099 12.04 5.22 x 10-04 
  rs9383938 G|T 0.080|0.112 15 1.08 x 10-04 
 rs9383938 rs3757322 T|G 0.328|0.379 16.27 5.49 x 10-05 
  rs9397437 G|A 0.070|0.099 0.52 0.47 
10p12.31 rs7072776 rs2183271 T|C 0.359|0.409 12 5.33 x 10-04 
 rs2183271 rs7072776 G|A 0.274|0.305 0.98 0.32 
11q13.3 rs78540526 rs75915166 C|A 0.051|0.073 0.22 0.64 
  rs554219 C|G 0.114|0.153 4.78 0.03 
 rs75915166 rs78540526 C|T 0.064|0.096 16.25 5.55 x 10-05 
  rs554219 C|G 0.115|0.155 16.55 4.74 x 10-05 
 rs554219 rs78540526 C|T 0.066|0.098 6.44 0.01 




Supplementary Figure 1: GWAS design and data quality control. Sources and 
numbers of case and control subjects contributing to each GWAS dataset are indicated in 
the top row of the figure, as are the SNP genotyping arrays which were used for genome-
wide genotyping. Sample and SNP exclusions are indicated alongside the reason for their 
exclusion. The total number of directly genotyped SNPs harmonised in cases and controls 
prior to 1KGP imputation is shown in the middle row. 
 
Supplementary Figure 2: QQ plots of association statistics. The distributions of the 
observed vs. expected P-values from 1,028 MBC cases (UK-BCN-MBCS, UK-UoC, UK-
UoL, US-CoH) genotyped using Illumina Infinium OmniExpress and 2,664 controls (UK-
58BC, UK-BCN-MBCS) that had been genotyped using Illumina 1.2M Duo arrays (A), 191 
cases (UK-BCN-MBCS) and 704 controls (UK-GS, UK-BCN-MBCS) genotyped using the 
Illumina Infinium Oncoarray (B) and 161 cases and 252 controls (UK-BCN-MBCS) 
genotyped using the Illumina Infinium Global Screening Array (C). Test statistic inflation 
(red line) was assessed using lambda statistics and the null distribution is indicated by the 
solid black line. 
 
Supplementary Figure 3: Manhattan plot of meta-analysed association data. -log10 P-
values for association with predisposition to MBC of 8,074,073 autosomal SNPs.  
 
Supplementary Figure 4: Forest plots for the loci subject to replication analysis. 
Forest plots and individual effect estimates, p-values and p-values for heterogeneity for 
each study that contributed to the replication dataset. 
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Supplementary Figure 5: Gene expression of candidate gene targets in normal male 
(n = 157) and female (n = 107) breast tissue samples. Boxes represent median, 25th 
and 75th percentiles of normalised gene count, whiskers indicate the lowest and highest 
values with 1.5 IQR of the lower and upper quartiles. Outliers are plotted as circles. P-
values were calculated using linear regression. 
 
Supplementary Figure 6: Box plots of eQTL analysis between predisposition SNPs 
and putative target genes in normal breast tissue (n = 264). For SNPs that had 
homozygote genotype counts < 10, analyses were performed on two genotype groups. 
Numbers of individuals with each given genotype are indicated on the x-axis. Boxes 
represent median, 25th and 75th percentiles of normalised gene count, whiskers indicate 
the lowest and highest values with 1.5 IQR of the lower and upper quartiles. Outliers are 
plotted as circles. 
 
Supplementary Figure 7: Interaction analysis of genotype and sex on gene 








Supplementary Figure 2: QQ plots of association statistics.  
 
Supplementary Figure 3: Manhattan plot of meta-analysed MBC GWAS data. 
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Supplementary Figure 5: Gene expression of candidate target genes in normal male 








Supplementary Figure 6: Box plots of eQTL analysis between predisposition SNPs 








Supplementary Figure 7: Interaction analysis of genotype and sex on gene 
expression.  
 
 
 
